Stock Ratings / Health Care / VYGR / dividends

LENZ (44) BDTX (59) ENGN (44) OTLK (38) ⌘ Pro Terminal →

Voyager Therapeutics Inc. (VYGR) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Is VYGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Voyager Therapeutics Inc. (NASDAQ: VYGR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.76 (-4.35% 1D, market cap $108.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VYGR ranks #1014 in composite RQD confidence.

Q: How does VYGR compare to LENZ and BDTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VYGR carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LENZ (LENZ Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -27.8%, cap $109.7M) and BDTX (Black Diamond Therapeutics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC 10.8%, cap $106.9M). Among the 5-stock peer group, VYGR leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for VYGR?

Per VYGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001640266), Voyager Therapeutics Inc. generated $40.4M in revenue (-49.5% YoY), -$119.7M in net income, and -$135.1M in free cash flow against $252.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is VYGR trading relative to its 50-day, 200-day, and 52-week technical levels?

VYGR last traded at $1.76 (-4.35% on volume of 659,901 shares), positioning the stock -35.06% below its 50-day simple moving average ($2.71) and -49.13% below its 200-day simple moving average ($3.46). Across its 52-week range of $1.68 to $5.48, VYGR sits at the 2.1% percentile with a 14-day RSI of 29.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.54 to $1.98).

Q: Does VYGR pay a dividend and is it safe?

Voyager Therapeutics Inc. (VYGR) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$1.76 -4.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.74

Voyager Therapeutics Inc. (VYGR) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $108.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.74 (-0.97%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-17.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VYGR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (19/100 Composite)

🔍 WHY VYGR SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (42% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 29.5 (OVERSOLD (<32))

▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.45-22.4% Next Q

Q2 (-2Q)

Grade E$1.90-8.4% Next Q

Q3 (-1Q)

Grade E$1.74+1.1% Next Q

Current

Grade E$1.76-12% Hist 90D α

Trajectory: E (27) → E (19)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VYGR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VYGR currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.71) and Max Pain ($1.85) forces dealer call-delta covering toward $5.75.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VYGR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VYGR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 19%NO 81%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VYGR)

✓Walkthrough of VYGR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VYGR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.82%▼ SUPPORT BREAKDOWN

2026-10-30O $1.75H $1.76L $1.68C $1.76VOL 878.8K

RES: $3.12SUP: $2.25SMA50: $2.71SMA200: $3.46

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VYGR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VYGR Butterfly Map → + Track VYGR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -49.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VYGR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VYGR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VYGR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VYGR)

Health Care Rank #1014 of 1016 ⚔️ LENZ vs VYGR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VYGR vs. LENZ, BDTX, ENGN, OTLK)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Voyager Therapeutics Inc. (VYGR) ranks #1014 by composite RQD confidence (19/100, grade E) and #648 by equity capitalization ($108.4M). Within this direct 5-issuer industry benchmark cohort, VYGR leads on earnings valuation at N/A trailing P/E, while BDTX leads on capital efficiency and profitability with 10.8% ROIC and — gross margin. BDTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with VYGR at 19/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VYGR ACTIVE Voyager Therapeutics Inc.	E	19/100	—	—	-35.0%	-4.35%	$108.4M	Benchmark Subject
LENZ LENZ Therapeutics Inc.	D	44/100	—	96.0%	-27.8%	+8.72%	$109.7M	/lenz-vs-vygr →
BDTX Black Diamond Therapeutics Inc.	C-	59/100	—	—	10.8%	+1.64%	$106.9M	/bdtx-vs-vygr →
ENGN enGene Therapeutics Inc.	D	44/100	—	—	-35.0%	-3.16%	$102.5M	/engn-vs-vygr →
OTLK Outlook Therapeutics Inc.	D-	38/100	—	4.0%	-35.0%	-9.43%	$120.1M	/otlk-vs-vygr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001640266

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Voyager Therapeutics Inc. (VYGR) reported GAAP revenue of $40.4M (-49.5% vs. FY2024 revenue of $80.0M , and -83.9% cumulative change since FY2023) , GAAP net income of -$119.7M, operating cash flow of -$132.5M, and free cash flow of -$135.1M (-617.2% YoY). On the balance sheet, VYGR closed FY2025 with $252.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$40.4M	-$119.7M	-$132.5M	-$135.1M	$252.3M	—
FY2024 (FY)	2024-12-31	$80.0M	-$65.0M	-$15.3M	-$18.8M	$393.1M	—
FY2023 (FY)	2023-12-31	$250.0M	$132.3M	$77.9M	$77.9M	—	—

3. VYGR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VYGR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Voyager Therapeutics Inc. (NASDAQ: VYGR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.76 (-4.35% 1D, market cap $108.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VYGR ranks #1014 in composite RQD confidence.

How does VYGR compare to LENZ and BDTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VYGR carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LENZ (LENZ Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -27.8%, cap $109.7M) and BDTX (Black Diamond Therapeutics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC 10.8%, cap $106.9M). Among the 5-stock peer group, VYGR leads on earnings multiple (N/A) while BDTX leads on capital efficiency (10.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VYGR?

Per VYGR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001640266), Voyager Therapeutics Inc. generated $40.4M in revenue (-49.5% YoY), -$119.7M in net income, and -$135.1M in free cash flow against $252.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VYGR trading relative to its 50-day, 200-day, and 52-week technical levels?

VYGR last traded at $1.76 (-4.35% on volume of 659,901 shares), positioning the stock -35.06% below its 50-day simple moving average ($2.71) and -49.13% below its 200-day simple moving average ($3.46). Across its 52-week range of $1.68 to $5.48, VYGR sits at the 2.1% percentile with a 14-day RSI of 29.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.54 to $1.98).

VYGR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does VYGR pay a dividend and is it safe?

Voyager Therapeutics Inc. (VYGR) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: VYGR RQD Cockpit VYGR 12M Forecast VYGR Earnings & Move VYGR Dividends & DRIP VYGR Insiders & 13F VYGR Whale Options VYGR Profit Sankey VYGR News & Why